Citations

Clear

371 citation(s) found for "Cho, M H".

African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma
Pilcher, William , Tang, Hongwei, Ferguson, Katherine, Foltz, Steven , Michaud, Marina E. , Satpathy, Sarthak , Shah, Nishi , Jin, Yuxin , Ohlstrom, Denis, Bakhtiari, Mojtaba , Acharya, Chaitanya R. , Gout, Alexander M. , Keats, Jonathan J. , Dhodapkar, Madhav V. , Avigan, David , Vij, Ravi, Kumar, Shaji , Cho, Hearn Jay , Vlachos, Ioannis S. , Ding, Li , Gnjatic, Sacha , Cole, Craig E. , Nooka, Ajay K. , Lonial, Sagar, Carpten, John, Baughn, Linda B. , Bhasin, Manoj

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033999 | PMID 42832384 Get It

The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
The Biomarker Revolution in Kidney Transplantation
Cho, Elizabeth , Lopez, Yvette Y, Alasfar, Sami

Mayo Clinic

Journal of Clinical Medicine | September 30, 2026 | Volume: 15 | Issue: 19 | Pages: 7601

10.3390/jcm15197601 | PMID 42882063 Get It

Since the first successful kidney transplant in 1954, transplant medicine has advanced significantly, achieving favorable one-year outcomes. However, despite excellent short-term outcomes, long-term renal allograft survival remains sub-optimal, with acute rejection continuing to be a major contributor to death-censored allograft loss. Current approaches for post-transplant surveillance and rejection monitoring rely on either nonspecific markers that often detect injury late in their course or invasive procedures associated with procedural risks and complications. To address these limitations, numerous non-invasive biomarkers have been introduced into solid organ transplantation research with the goal of improving allograft surveillance, facilitating earlier detection of rejection and complementing existing diagnostic approaches. Although several biomarkers have demonstrated clinical promise, none currently possess sufficient accuracy to replace kidney allograft biopsy. Biomarkers under investigation include blood-, tissue- and urine-based specimens. Their development and validation as independent markers have been limited by smaller sample size, heterogenous targets, variable performance characteristics and suboptimal sensitivity and specificity. In response, the field has increasingly shifted toward multimodal approaches that combine biomarkers and incorporate artificial intelligence to improve diagnostic accuracy and outcomes prediction. This review summarizes current biomarkers, discusses their limitations and explores future directions for biomarker development and clinical implementation.
P4.810: Donor APOL1 high-risk genotypes and early graft failure: Two cases of De Novo collapsing FSGS with second hits.
Alasfar, Sami , Alanzi, Meshaal , Sridhara, Srilekha , Me, Hay Me , Fu, Lily, Ryan, Maggie, Alanzi, Meshaal , Cho, Elizabeth , Jawdeh, Bassam G. Abu

Mayo Clinic

Transplantation | August 31, 2026 | Volume: 110 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001254760.98976.87 Get It

Platelet Reactivity and Sex Differences: Clinical Implications for Women
Aggarwal, Anu , Barrett, Tessa J. , Mehta, Puja K. , Honigberg, Michael C. , Cosemans, Judith M.E.M. , Goodman, Wendy A. , Aggarwal, Niti R., Holinstat, Michael , Cho, Leslie , Cameron, Scott J. , Honigberg, Michael C , Cameron, Scott J

Mayo Clinic

Circulation Research | August 13, 2026 | Volume: 139 | Issue: 5 | Pages: No page available

10.1161/circresaha.126.328602 | PMID 42594167 Get It

Platelets are central to hemostasis and thrombosis. Excessive platelet activation contributes to arterial thrombotic events, including myocardial infarction, ischemic stroke, and complications of peripheral artery disease, whereas excessive platelet inhibition increases bleeding risk. Antiplatelet therapy remains a cornerstone of secondary prevention in atherosclerotic and thrombotic cardiovascular diseases, yet current treatment paradigms do not fully account for biological heterogeneity in platelet function, including differences related to sex, age, hormonal status, and disease context. This state-of-the-art review examines current antiplatelet strategies, fundamental mechanisms of signal transduction, clinical indications, and limitations of preclinical and clinical studies, with a focus on sex-specific considerations and opportunities for personalized antiplatelet therapy. Aspirin and P2Y 12 receptor antagonists are widely used for secondary prevention. However, women have been underrepresented in many pivotal clinical trials, limiting the precision of sex-specific estimates of efficacy and bleeding risk. In parallel, commonly used preclinical models often fail to recapitulate the physiological conditions in which platelets interact with the vasculature, leukocytes, and soluble factors. Emerging therapeutic approaches seek to refine platelet inhibition by targeting pathways that reduce thrombotic risk while preserving hemostasis. Advancing antiplatelet therapy will require integration of mechanistic platelet biology with diverse clinical trial populations, standardized platelet phenotyping, and disease-specific approaches that account for how platelet function is altered across health and vascular disease.
Integrated coding-noncoding genome annotation expands single-cell transcriptomic discovery and identifies clinically relevant noncoding RNAs in multiple myeloma
Bakhtiari, Mojtaba , Henderson, Edward, Ferguson, Katherine , Pilcher, William C., Gonzalez-Kozlova, Edgar, Karagkouni, Dimitra, Matulis, Shannon M. , Acharya, Chaitanya R., Avigan, David, Vij, Ravi, Parekh, Samir, Ding, Li, Kumar, Shaji, Nooka, Ajay, Mulligan, George, Lonial, Sagar, Bhasin, Manoj, Michaud, Marina E. , Ohlstrom, Denis , Satpathy, Sarthak , Pilcher, William , Gonzalez‐Kozlova, Edgar , Karagkouni, Dimitra , Acharya, Chaitanya R. , Avigan, David , Vij, Ravi , Parekh, Samir , Cho, Hearn Jay , Vlachos, Ioannis S. , Kumar, Shaji , Gnjatic, Sacha , Nooka, Ajay K. , Lonial, Sagar , Boise, Lawrence , Bhasin, Manoj K

Mayo Clinic

No container title available | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.09.743753 Get It

Abstract Although the human genome encodes a vast repertoire of noncoding RNAs that regulate gene expression, the noncoding genome remains underexplored due to technical challenges. Specifically, during transcriptomic sequencing data alignment, the overlap between noncoding and coding loci can create ambiguous read alignments that are subsequently discarded from downstream analysis. For this reason, most of the noncoding genome is excluded from standard genomic annotations used for sequencing alignment. To address this challenge and enable concurrent profiling of the coding and noncoding transcriptome, we systematically integrated standard coding (GENCODE) and noncoding (LncBook) genome annotations, preserving coding gene annotations and removing overlapping noncoding regions. The resulting integrated genome annotation expanded the number of annotated noncoding genes from 40,785 to 138,296 while preserving all coding genes and reducing ambiguous read assignment. To evaluate the utility of our integrated genome annotation for uncovering novel, biologically relevant noncoding RNAs (ncRNAs), we realigned CD138-positive bulk RNA-seq (N = 942) and CD138-negative single-cell RNA-seq (N = 478) data from the MMRF CoMMpass study, generating a comprehensive coding-noncoding atlas of the myeloma bone marrow microenvironment with noncoding genes representing 51% of highly variable genes and displaying significant cell type specificity. Tumor expression profiling based on this integrated profiling identified 15 clusters, including two enriched for amp(1q21) or t(4;14) and associated with shorter progression-free survival (PFS). Differential expression and systematic filtering yielded 19 candidate high-risk ncRNAs, including previously uncharacterized ENSG00000310209 , which was associated with poor PFS (HR = 1.141, P = 0.0025), increased IRF4 activity, Wnt pathway activation, CCL5 signaling, and the accumulation of anergic-like CD8+ T cells. These findings establish integrated coding-noncoding analysis as a strategic approach for discovering functional ncRNAs from transcriptomic sequencing data.
Provider Perspectives on Community Birth Transfers: Analysis of Personal Values and Attitudes Toward Community Birth Among Maternity Care Providers in Community and Hospital Settings
Shao, Samantha, Unadkat, Krishna, Li, Yan, Geldmaker, Laura, Cho, Courtney McEwen, Lamppa, Julie, Smith, Rebecca , Larish, Alyssa , McEwen Cho, Courtney, Geldmaker, Laura , Lamppa, Julie A.

Mayo Clinic

Journal of Midwifery & Women's Health | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jmwh.70167 | PMID 42576725 Get It

Introduction Out‐of‐hospital community births account for 1.6% to 2% of births in the United States and are associated with fewer obstetric interventions but increased neonatal risk. Little is known about how maternity care providers’ characteristics, values, and prior exposure to community birth influence attitudes toward community birth. Methods We conducted an observational cross‐sectional survey using a 40 to 43 item Research Electronic Data Capture questionnaire distributed October 2 to 30, 2024. Eligible participants (“providers”) included in‐hospital physicians, midwives, community birth providers, and registered nurses. The survey assessed demographics, practice characteristics, provider values, prior community birth experience, and attitudes toward community birth. Descriptive statistics were used to summarize characteristics. Group comparisons between in‐hospital and community birth providers were conducted using analysis of variance and χ 2 or Fisher exact tests. Associations between attitudes and provider values were evaluated using linear models with Bonferroni correction. Results Sixty‐seven providers completed the survey (51 in hospital, 16 community based). Most respondents were female (89.6%) and White (77.6%), with a median of 7 years in practice (IQR, 3‐14.5). Attitudes significantly differed by role ( P = .007) and credentials ( P = .002). In‐hospital providers reported safety concerns about community birth and perceived antenatal counseling to be inadequate. Perceived patient distrust during transfer was common among both in‐hospital and community‐based providers (69% and 81%, respectively). After adjustment for provider role and multiple comparisons, no significant differences in personal values were noted by attitude group; however, providers with positive attitudes toward community birth were more likely to believe that patients value compassion (β = 2.3, P = .004). Discussion Provider attitudes toward community birth appear to be shaped more by professional role and clinical experience than by differences in underlying value systems. High levels of perceived patient distrust during transfer highlight the need for interventions that strengthen compassion across maternity care settings.
The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists
Lee, Hyunsuk , Christie, Hannah E. , Lee, Ji Seon , Kwon, Woo Il, Moon, Min Kyong , Choi, Sung Hee , Lee, Dae Ho , Lee, Seunggeun , Kho, Minjung , Man, Chiara Dalla , Cho, Nam H. , Park, Jongseok , Jo, Yeeun , Boscolo, Federica , Dalla Man, Chiara , Cho, Nam H , Choi, Jaewon , Vella, Adrian , Kwak, Soo Heon , Kim, Jong-Il , Park, Kyong Soo , Christie, Hannah E , Lee, Hyunbeom , Boscolo, Francesca S. , Lee, Jeongeun, Lee, Sangwon , Vella, Adrian

Mayo Clinic

Diabetes Care | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/dc26-0662 | PMID 42561183 Get It

OBJECTIVE Genetic variation in the glucagon-like peptide 1 receptor (GLP1R) has been implicated in type 2 diabetes (T2D) risk and treatment response. We investigated whether GLP1R R131Q, which was previously reported as a T2D-protective variant in genome-wide association studies, alters receptor signaling, β-cell function, and response to glucagon-like peptide 1 receptor agonists (GLP-1RAs). RESEARCH DESIGN AND METHODS Trajectory of β-cell function was evaluated in a 20-year community-based prospective cohort in Korea (n = 6,373), where participants underwent biennial 2-h 75-g oral glucose tolerance tests, and disposition index was used as surrogate marker. Pharmacogenetic response to GLP-1RAs was assessed in a hospital-based T2D cohort in Korea (n = 177). Hyperglycemic clamp studies (n = 17), human islet experiments (n = 21), and in vitro assays were conducted to characterize GLP1R R131Q effects on receptor signaling and islet function. RESULTS GLP1R R131Q was associated with slower decline in disposition index in individuals without T2D, with reductions from baseline of 30% in homozygous carriers, 35% in heterozygotes, and 37% in wild-type individuals. In people with T2D, each allele conferred an additional 0.53% or 5.8 mmol/mol reduction in HbA1c after 6 months of GLP-1RA treatment (P = 5.8 × 10−4). Hyperglycemic clamp and human islet experiments demonstrated allele-dependent enhancement of GLP-1RA–stimulated insulin secretion (P = 0.050 and P = 0.037, respectively). In vitro, GLP1R R131Q increased GLP-1RA–stimulated cAMP production with directional observations consistent with pathway bias. CONCLUSIONS GLP1R R131Q is a gain-of-function variant associated with preservation of β-cell function and enhanced glycemic response to GLP-1RA treatment, supporting further investigation as a candidate pharmacogenetic marker for precision diabetes care.
Microbial Diversity in Odontogenic Sinusitis: Next-Generation Sequencing Versus Culture
Abdurrob, Abdurrahman , Ancira, Jacob S., Tipton, Craig, Hanna, Zachary, Craig, John, Cho, Do‐Yeon , Eide, Jacob G. , Ray, Amrita , Ancira, Jacob , Tipton, Craig D. , Hanna, Zachary W

Mayo Clinic

American Journal of Rhinology & Allergy | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19458924261474104 | PMID 42530539 Get It

Background Odontogenic sinusitis (ODS) is a common cause of unilateral infectious maxillary sinusitis but is frequently underdiagnosed due to nonspecific symptoms, subtle dental findings on imaging, and limitations of traditional bacterial cultures—particularly for anaerobic organisms. Next-generation DNA sequencing (NGS) may enhance detection of odontogenic bacteria. Objective This study compared bacterial detection between standard cultures versus NGS in patients with confirmed ODS. Methods Twenty consecutive adults with confirmed ODS were enrolled. Maxillary sinus purulence was collected endoscopically and submitted for routine aerobic and anaerobic bacterial cultures and for NGS-based microbial profiling using 16S rRNA gene sequencing. Detected organisms were categorized by aerotolerance and ODS relationship, and likely nasal colonizers were excluded from analyses. Alpha diversity, beta diversity, and compositional differences between methods were analyzed statistically. Results NGS detected significantly more bacterial species per specimen than culture (mean 4.9 vs 2.7; P = .0015). Compared to cultures, NGS identified more anaerobic bacteria (4.2 vs 0.9; P = .00004) and more ODS-related species (4.4 vs 1.0; P = .0001), while detection of aerobic species was similar between methods. Cultures also often yielded nonspeciated results, whereas NGS consistently revealed polymicrobial communities dominated by oral anaerobes. Microbial composition differed significantly between detection methods. Conclusion In confirmed ODS, NGS detected significantly more anaerobic and ODS-related species than culture from the same specimens. These findings suggest that culture alone may underestimate odontogenic contributions to purulent sinusitis. Future studies should explore he utility of NGS as an adjunctive tool to facilitate diagnosis and treatment in the setting of possible ODS.
Single-electrode simultaneous detection of tonic dopamine and serotonin in vivo using an interleaved cyclic square wave voltammetry approach
Cho, Hyun-U., Hwang, Sangmun, Kwak, Youngjong , Kwon, Haeun , Jang, Jaehyun , Shin, Hojin, Lee, Kendall H., Jang, Dong Pyo, Kim, Kyung Min , Oh, Yoonbae , Lee, Kendall H., Jang, Dong Pyo

Mayo Clinic

Analytical Methods | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1039/d6ay00711b | PMID 42528485 Get It

We report an innovative interleaved voltammetric strategy to simultaneously quantify tonic levels of dopamine and serotonin in vivo using a single unmodified microelectrode, advancing our capability to monitor complex neurochemical interactions.
Cardiovascular Health Across the Life Course for Individuals With Breast Cancer
Mauricio, Rina, Deswal, Anita, Ruddy, Kathryn J., Chen, Ming Hui, Ebong, Imo A., Aggarwal, Niti R., Harrington, Colleen , Barcenas, Carlos H., Mitchell, Melissa P. , Cho, Leslie , Nohria, Anju, Mauricio, Rina , Deswal, Anita M , Ruddy, Kathryn J. , Akhter, Nausheen , Ebong, Imo , Barcenas, Carlos Hernando , Nohria, Anju

Mayo Clinic

JAMA Cardiology | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2546 | PMID 42525430 Get It

Importance Breast cancer is the most common cancer diagnosed in women. Therapies for breast cancer are evolving rapidly, and several are associated with cardiovascular adverse effects, can exacerbate cardiovascular risk factors, or can increase the risk of cardiovascular disease. Observations Advances in screening and treatment have led to earlier diagnosis and improved disease-free survival. For long-term survivors of breast cancer, cardiovascular adverse effects can pose a greater threat to overall long-term health than the cancer itself. Additionally, the increasing incidence of breast cancer in younger, premenopausal women has created a distinct demographic with unique medical needs. Conclusions and Relevance Cardiology practitioners need to remain updated on rapidly evolving breast cancer therapies to care for this growing, unique patient population. The field of cardio-oncology has evolved to address the cardiovascular needs of patients and survivors.